SCHEMBL904727

SCHEMBL904727

CCn1cc2cc(CN3C(=O)c4ccccc4C3=O)ccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.50
▸ PABPC1 P11940 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ KMT2A Q03164 3/20 0.44
▸ PKM P14618 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP1B1 Q16678 1/20 0.42
▸ CASP3 P42574 3/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ TYR P14679 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205148 0.75 MAPT (0.56) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL904586 0.73 SLC5A2 (0.46) HPGDHTTSMN1; SMN2HDAC6
SCHEMBL1163336 0.73 CYP1B1 (0.69) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL2569297 0.73 PABPC1 (0.60) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL904639 0.72 PABPC1 (0.56) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL1206885 0.70 PABPC1 (0.48) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL6526615 0.70 CYP1B1 (0.53) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL1206339 0.70 ALOX15 (0.48) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL19398817 0.69 RPS6KA2 (0.63) HPGDPABPC1ALOX15MAPK1MAPT
SCHEMBL19200547 0.69 PABPC1 (0.59) HPGDPABPC1ALOX15MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 — — US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 — — US disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM6, TRPM5 HPGD 1552/4885PABPC1 4479/4885ALOX15 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback